Emerging therapies for adult soft tissue sarcoma. (Q34659806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

review article

1 reference

title

Emerging therapies for adult soft tissue sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Silvia Stacchiotti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Paolo Giovanni Casali

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alessandro Gronchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Paolo Giovanni Casali

3

object named as

Paolo G Casali

1 reference

3 August 2017

Stefano Radaelli

1

1 reference

3 August 2017

Sivia Stacchiotti

2

1 reference

3 August 2017

Alessandro Gronchi

4

1 reference

3 August 2017

publication date

20 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

689-704

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555529%20AND%20SRC:MED&resulttype=core&format=json

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The epidemiology of sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sarcoma epidemiology and etiology: potential environmental and genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Advances in sarcoma genomics and new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Novel pathways and molecular targets for the treatment of sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Targeted therapies in sarcomas: challenging the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The molecular biology of soft-tissue sarcomas and current trends in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

New therapeutic targets in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Soft-tissue sarcomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Combined modalities approach for localized adult extremity soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Retroperitoneal tumours: review of management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A Systematic Overview of Radiation Therapy Effects in Soft Tissue Sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pulmonary metastasectomy for soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Trabectedin therapy for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Trabectedin: Safety and Efficacy in the Treatment of Advanced Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Adjuvant therapy for high-risk soft tissue sarcoma in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Chemotherapy in alveolar soft part sarcomas. What do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Chemotherapy in clear cell sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Efficacy of trabectedin in metastatic solitary fibrous tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Curent concepts in pathology of soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Endometrial stromal sarcoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pazopanib in the treatment of soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Pazopanib in sarcomas: expanding the PALETTE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sunitinib malate in solitary fibrous tumor (SFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Response to sunitinib malate in advanced alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Tumor response to sunitinib malate observed in clear-cell sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Cediranib: a VEGF receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Cediranib for metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Objective response to sorafenib in advanced clear-cell sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sorafenib is active on lung metastases from synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Updating progress in sarcoma therapy with mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Myxoid liposarcoma and the mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Lymphangioleiomyomatosis: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Current phase II clinical data for ridaforolimus in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Emerging therapies for soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Notch, wnt, and hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Clinical implications of hedgehog signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840

Positive Surgical Margins in Soft Tissue Sarcoma Treated With Preoperative Radiation: Is a Postoperative Boost Necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.885840